Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Non-Standardized Pollen Allergenic Extract [EPC]
Juniperus Occidentalis Pollen is a non-standardized allergenic extract used for the diagnosis and treatment of seasonal allergies caused by Western Juniper. It belongs to the class of Non-Standardized Pollen Allergenic Extracts [EPC].
Name
Juniperus Occidentalis Pollen
Raw Name
JUNIPERUS OCCIDENTALIS POLLEN
Category
Non-Standardized Pollen Allergenic Extract [EPC]
Drug Count
5
Variant Count
5
Last Verified
February 17, 2026
About Juniperus Occidentalis Pollen
Juniperus Occidentalis Pollen is a non-standardized allergenic extract used for the diagnosis and treatment of seasonal allergies caused by Western Juniper. It belongs to the class of Non-Standardized Pollen Allergenic Extracts [EPC].
Detailed information about Juniperus Occidentalis Pollen
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Juniperus Occidentalis Pollen.
Juniperus Occidentalis Pollen, commonly known as Western Juniper pollen, is a biological substance used in clinical immunology for the diagnosis and treatment of allergic conditions triggered by this specific tree species. It belongs to the pharmacological class known as Non-Standardized Pollen Allergenic Extracts [EPC]. These extracts are derived from the male cones of the Juniperus occidentalis tree, which is native to the mountainous regions of the Western United States, particularly in Oregon, California, and Nevada.
In clinical practice, Juniperus Occidentalis Pollen is primarily utilized in two ways: as a diagnostic tool for skin testing (to confirm sensitivity) and as an immunotherapy agent (commonly referred to as 'allergy shots'). The goal of using this extract is to modify the patient's immune response to the allergen over time. While many modern drugs are synthetic chemicals, allergenic extracts are complex biological mixtures containing proteins, glycoproteins, and polysaccharides that constitute the allergenic profile of the plant. The FDA regulates these extracts under the Center for Biologics Evaluation and Research (CBER), and while many are 'non-standardized'—meaning they are not measured by a specific potency unit like Bioequivalent Allergy Units (BAU)—they are manufactured under strict current Good Manufacturing Practices (cGMP) to ensure consistency and safety.
Juniperus Occidentalis Pollen works through a process known as allergen immunotherapy (AIT). When a patient is allergic to Western Juniper, their immune system overreacts to the pollen by producing Immunoglobulin E (IgE) antibodies. These antibodies bind to mast cells and basophils. Upon subsequent exposure to the pollen, the allergen cross-links the IgE on these cells, triggering the release of inflammatory mediators like histamine, leukotrienes, and cytokines, which result in the symptoms of hay fever (allergic rhinitis) or asthma.
At the molecular level, the administration of Juniperus Occidentalis Pollen extract in gradually increasing doses (desensitization) induces a shift in the immune system's T-cell response. Specifically, it encourages a move away from a Th2-dominated response (which promotes IgE and allergy) toward a Th1-dominated response or the induction of regulatory T-cells (Tregs). This shift leads to the production of 'blocking antibodies' known as IgG4. These IgG4 antibodies compete with IgE for the allergen, effectively neutralizing the pollen before it can trigger an allergic reaction. Furthermore, long-term treatment reduces the recruitment of eosinophils and mast cells to the mucosal surfaces of the nose and eyes, providing long-lasting relief from symptoms.
Traditional pharmacokinetics (absorption, distribution, metabolism, and excretion) do not apply to allergenic extracts in the same way they do to small-molecule drugs. Because these are biological proteins injected subcutaneously or applied topically to the skin, their 'action' is localized and immunological rather than systemic and metabolic.
Juniperus Occidentalis Pollen extract is FDA-indicated for the following uses:
Juniperus Occidentalis Pollen is available in the following pharmaceutical forms:
> Important: Only your healthcare provider can determine if Juniperus Occidentalis Pollen is right for your specific condition. Immunotherapy should only be administered by clinicians trained in the management of allergic diseases and equipped to handle emergency reactions.
Dosage for Juniperus Occidentalis Pollen is highly individualized and must be determined by an allergist based on the patient's sensitivity levels. There is no 'standard' dose for all patients.
Treatment typically begins with a very low dose of a highly diluted extract (e.g., 1:100,000 w/v or 1 PNU/mL). Injections are usually given once or twice a week. The dose is gradually increased with each injection until the 'maintenance dose' is reached. This phase usually lasts 3 to 6 months.
Once the maintenance dose (the highest dose tolerated without significant side effects) is reached, the frequency of injections is decreased to once every 2 to 4 weeks. This phase is typically continued for 3 to 5 years to achieve long-term desensitization.
Juniperus Occidentalis Pollen is generally considered safe and effective for children, typically those aged 5 years and older. The dosing schedule for children follows the same principles as adult dosing, starting with low-concentration dilutions and gradually increasing based on individual tolerance. Children should be closely monitored for systemic reactions, as they may have more difficulty communicating early symptoms of anaphylaxis.
No specific dose adjustments are required for patients with renal impairment, as the extract is not cleared via the kidneys in a manner that affects systemic toxicity. However, the patient's overall health should be considered.
No dose adjustments are necessary for hepatic impairment, as the metabolism of allergenic proteins does not involve the liver's metabolic pathways.
Caution is advised in elderly patients, particularly those with underlying cardiovascular disease. The risk of using epinephrine (required to treat a potential reaction) must be weighed against the benefits of immunotherapy in this population.
If a dose is missed during the build-up phase, the next dose may need to be reduced or the previous dose repeated to maintain safety. If a dose is missed during the maintenance phase, the healthcare provider will determine if a dose adjustment is necessary based on how much time has passed. Do not attempt to 'double up' on doses to make up for a missed one.
An 'overdose' in the context of immunotherapy refers to an injection of a concentration higher than what the patient can tolerate, leading to a systemic reaction.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance. Ensure your provider is aware of any new medications or health changes before each injection.
Most patients undergoing immunotherapy with Juniperus Occidentalis Pollen will experience local reactions. These are generally not dangerous but can be uncomfortable.
> Warning: Stop taking Juniperus Occidentalis Pollen and call your doctor immediately or seek emergency care if you experience any of these symptoms of anaphylaxis.
There are no known long-term 'toxic' side effects of Juniperus Occidentalis Pollen extract. The primary long-term effect is the intended modification of the immune system. However, patients who receive immunotherapy for many years may develop a persistent sensitivity to the injection site or, in very rare cases, granulomas (small knots of tissue) at the site of repeated injections.
Most allergenic extracts, including Juniperus Occidentalis Pollen, carry a warning regarding the risk of severe systemic reactions.
Summary of Warning: Juniperus Occidentalis Pollen extract can cause severe, life-threatening systemic reactions, including anaphylaxis. Because of this risk, it should only be administered in a medical setting by personnel prepared to treat such reactions. Patients with unstable asthma are at a higher risk for fatal reactions. Patients must be observed for at least 30 minutes following administration. Some patients may also experience delayed reactions that occur after they leave the clinic.
Report any unusual symptoms to your healthcare provider. Even a large local reaction should be reported, as it may be a precursor to a systemic reaction at the next, higher dose.
Juniperus Occidentalis Pollen is a potent biological product. Safety depends on accurate diagnosis, precise dosing, and careful monitoring. Patients must be communicative with their healthcare team regarding any changes in their health, especially respiratory health, before receiving an injection.
No FDA black box warnings for Juniperus Occidentalis Pollen. (Note: While many allergenic extracts have class-wide warnings in their prescribing information regarding anaphylaxis, they do not always carry a formal 'Black Box' in the same way as high-risk synthetic drugs like antidepressants or anticoagulants. However, the risk of anaphylaxis is the primary clinical concern and is treated with equivalent gravity in all clinical literature.)
Juniperus Occidentalis Pollen does not typically cause sedation. However, if a patient experiences a mild systemic reaction or receives epinephrine for a reaction, they should not drive or operate machinery until they are fully recovered and cleared by a professional.
There is no direct chemical interaction between alcohol and Juniperus Occidentalis Pollen. However, alcohol can cause vasodilation (widening of blood vessels), which may theoretically increase the rate of allergen absorption or worsen the symptoms of an allergic reaction. It is best to avoid alcohol for several hours after an injection.
If immunotherapy is discontinued, the patient's sensitivity to Western Juniper will likely return over time, though some degree of lasting tolerance may remain. There is no 'withdrawal syndrome' associated with stopping allergenic extracts, but the clinical benefits will eventually diminish.
> Important: Discuss all your medical conditions with your healthcare provider before starting Juniperus Occidentalis Pollen, especially any history of heart problems or severe asthma.
There are no known direct food interactions with Juniperus Occidentalis Pollen. However, patients with 'Oral Allergy Syndrome' (OAS) may find that eating certain fruits or vegetables that cross-react with juniper proteins (though rare for this specific species) might increase their overall allergic sensitivity.
There is limited data on herbal interactions. However, supplements that affect the immune system (like echinacea or high-dose steroids) or those that have stimulant effects (like ephedra or high caffeine) should be discussed with an allergist, as they may influence the body's reaction to the extract or the treatment of a reaction.
Juniperus Occidentalis Pollen extract will directly affect the results of:
For each major interaction, the mechanism is usually either pharmacodynamic (affecting how the body responds to the allergen or the rescue medication) rather than pharmacokinetic (affecting drug levels).
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially any medications for blood pressure or heart rhythm.
Patients allergic to Juniperus Occidentalis may also be sensitive to other members of the Cupressaceae family, including:
Cross-reactivity is common within this family, and a patient sensitive to one may react to another. This must be considered when formulating a multi-allergen treatment vial.
> Important: Your healthcare provider will evaluate your complete medical history, including your heart and lung health, before prescribing Juniperus Occidentalis Pollen.
Pregnancy Category C. There are no adequate and well-controlled studies of Juniperus Occidentalis Pollen in pregnant women.
It is not known whether the components of Juniperus Occidentalis Pollen extract are excreted in human milk. Because the extract consists of naturally occurring proteins that are processed locally by the immune system, it is generally considered unlikely to pose a risk to a nursing infant. The benefits of allergy control for the mother should be weighed against any theoretical risks.
Immunotherapy is widely used in children, typically starting around age 5. Younger children may be treated if the allergy is severe, but the challenge lies in their ability to cooperate with injections and report early symptoms of a reaction. Studies have shown that immunotherapy can prevent the development of asthma in children with allergic rhinitis.
Elderly patients (over 65) require a careful cardiovascular assessment. The 'standard' dose may be tolerated, but the elderly are more likely to have comorbidities (like hypertension or coronary artery disease) that make a systemic reaction or the use of epinephrine riskier. Dose adjustments are based on clinical tolerance rather than age-related clearance changes.
No dosage adjustment is required for patients with renal impairment. The biological proteins in the extract are degraded by cellular proteases and do not rely on renal filtration for clearance.
No dosage adjustment is required for patients with hepatic impairment. The liver's metabolic enzymes (CYP450) are not involved in the processing of allergenic extracts.
> Important: Special populations require individualized medical assessment. Always inform your allergist if you become pregnant or develop new health conditions during treatment.
Juniperus Occidentalis Pollen extract acts as an immunomodulator. In an allergic individual, the immune system produces IgE antibodies in response to the proteins found in the pollen (such as the major allergen Jun o 1). When the extract is injected subcutaneously, it is taken up by dendritic cells and presented to T-lymphocytes.
Repeated exposure to increasing doses leads to the induction of Regulatory T-cells (Tregs), which secrete anti-inflammatory cytokines like IL-10 and TGF-beta. This suppresses the Th2 response, reduces the production of IgE, and stimulates B-cells to produce IgG4. IgG4 acts as a 'blocking antibody' by binding to the pollen allergens before they can reach the IgE on the surface of mast cells, thereby preventing the allergic cascade.
The pharmacodynamic effect of Juniperus Occidentalis Pollen is measured by a decrease in skin reactivity (smaller wheal and flare) and a reduction in clinical symptoms during the pollen season. The onset of effect is slow, often taking 3 to 6 months to notice improvement, with maximal benefit usually seen after 12 to 24 months of consistent treatment.
| Parameter | Value |
|---|---|
| Bioavailability | N/A (Subcutaneous/Local) |
| Protein Binding | N/A (Immunological interaction) |
| Half-life | Proteins: Minutes to Hours; Immunological Effect: Months |
| Tmax | N/A |
| Metabolism | Cellular Proteolysis |
| Excretion | Cellular waste/Lymphatic drainage |
Juniperus Occidentalis Pollen is classified as an Allergenic Extract. It belongs to the broader category of 'Biologicals' and is specifically grouped with other tree pollen extracts used for immunotherapy and diagnostic testing.
Common questions about Juniperus Occidentalis Pollen
Juniperus Occidentalis Pollen extract is used for the diagnosis and treatment of allergies to Western Juniper trees. For diagnosis, it is applied to the skin during a 'prick test' to see if a localized allergic reaction occurs. For treatment, it is used in allergen immunotherapy, commonly known as allergy shots. This involves giving gradually increasing doses of the pollen extract to help the immune system build up a tolerance. Over time, this reduces symptoms like sneezing, itchy eyes, and congestion during the juniper pollination season.
The most common side effects are localized reactions at the site of the injection. These include redness, swelling, and itching, which usually appear within a few hours and resolve within a day. Some patients may also experience a small, hard bump at the injection site. Mild systemic symptoms, such as increased sneezing or a stuffy nose shortly after the injection, can also occur. While common, these side effects are usually manageable and are a sign that the immune system is responding to the extract.
There is no direct interaction between alcohol and the pollen extract itself. However, healthcare providers often recommend avoiding alcohol for several hours after an allergy shot. Alcohol can cause blood vessels to dilate, which might speed up the absorption of the allergen into your bloodstream, potentially increasing the risk of a systemic reaction. Additionally, alcohol can sometimes worsen allergy symptoms or make it harder to recognize the early signs of a serious reaction. Always follow the specific advice provided by your allergist.
Juniperus Occidentalis Pollen is generally not started during pregnancy because of the risk of a severe allergic reaction (anaphylaxis), which could deprive the developing baby of oxygen. However, if a woman is already on a stable maintenance dose and is tolerating the injections well, most allergists will continue the treatment. The dose is typically not increased while the patient is pregnant to minimize risks. If you are planning to become pregnant or find out you are pregnant while on immunotherapy, you must inform your doctor immediately.
Allergen immunotherapy is a long-term treatment process and does not provide immediate relief like an antihistamine. Most patients begin to notice a reduction in their allergy symptoms after 3 to 6 months of treatment, once they reach a higher dose. However, the full benefits are typically not realized until the patient has been on a maintenance dose for 12 to 24 months. For lasting results that continue after the treatment is stopped, a full course of 3 to 5 years is generally recommended by clinical guidelines.
Yes, you can stop taking Juniperus Occidentalis Pollen injections suddenly without experiencing a 'withdrawal' or physical illness. However, stopping the treatment before the recommended 3-to-5-year course is complete will likely result in the return of your allergy symptoms over time. The 'tolerance' your immune system built up may fade if the process is interrupted too early. If you need to stop treatment due to side effects or lifestyle changes, discuss the best transition plan with your allergist.
If you miss a dose, contact your allergist's office to reschedule as soon as possible. Do not try to make up for the missed dose by taking more later. Depending on how long it has been since your last injection, your doctor may need to repeat your previous dose or even reduce the dose slightly to ensure your safety. This is especially important during the 'build-up' phase when your body is still getting used to the allergen. Consistency is key to the success of immunotherapy.
There is no clinical evidence to suggest that Juniperus Occidentalis Pollen extract causes weight gain. Unlike systemic corticosteroids (which are sometimes used for severe allergies and can cause weight changes), allergenic extracts are proteins that work specifically on the immune system's response to pollen. They do not affect your metabolism, appetite, or fat storage. If you notice unexpected weight changes while on this treatment, it is likely due to other factors and should be discussed with your primary care physician.
Most medications, such as birth control, thyroid medicine, and vitamins, are perfectly safe to take with Juniperus Occidentalis Pollen. However, certain medications like beta-blockers (used for heart conditions) and ACE inhibitors can make allergy shots more dangerous by interfering with the treatment of a potential allergic reaction. You must provide your allergist with a complete list of all medications you are taking. They will determine if any of your current prescriptions make immunotherapy unsafe for you.
The concept of 'generic' vs. 'brand name' is different for allergenic extracts than for pills. Because these are biological products derived from natural sources, different manufacturers may produce Juniperus Occidentalis Pollen extract, and they are generally considered interchangeable if the concentration (PNU or w/v) is the same. However, because these are non-standardized extracts, allergists often prefer to stay with the same manufacturer's product throughout a patient's treatment course to ensure the most consistent potency and safety.